Is it safe to switch a 270‑lb double‑amputee with a prior pulmonary embolism from warfarin (Coumadin) to apixaban (Eliquis) to avoid routine INR monitoring, assuming her creatinine clearance is ≥30 mL/min and she has no contraindications?

Switching from Warfarin to Apixaban: Safe and Strongly Recommended

Yes, it is safe and clinically appropriate to switch this patient from warfarin to apixaban, and this transition will eliminate the need for routine INR monitoring while providing equal or superior stroke prevention with significantly lower bleeding risk. 1, 2

Why Apixaban is the Right Choice

Apixaban demonstrated superiority over warfarin in the ARISTOTLE trial with an 11% relative risk reduction in stroke/systemic embolism (HR 0.79, P<0.001), a 49% reduction in hemorrhagic stroke (0.24%/year vs 0.47%/year), a 31% reduction in major bleeding (HR 0.69, P<0.001), and a 58% reduction in intracranial bleeding (HR 0.42, P<0.001). 2 This high-quality randomized trial evidence makes apixaban a Class I recommendation over warfarin for nonvalvular atrial fibrillation. 1, 2

Determining the Correct Apixaban Dose

The "2-of-3" Rule (FDA-Approved Algorithm)

Use apixaban 5 mg twice daily UNLESS the patient meets at least TWO of these three criteria: 1, 3, 4

1. Age ≥ 80 years
2. Body weight ≤ 60 kg (132 lbs)
3. Serum creatinine ≥ 1.5 mg/dL

For a 270-lb double-amputee with prior PE and CrCl ≥30 mL/min: 1, 3

• Weight = 270 lbs (122.5 kg) → does NOT meet the ≤60 kg criterion
• If age <80 years → does NOT meet age criterion
• If serum creatinine <1.5 mg/dL → does NOT meet creatinine criterion

Therefore, prescribe apixaban 5 mg twice daily (the standard dose). 1, 3, 4

Critical Dosing Pitfall to Avoid

Do NOT reduce the dose based on a single criterion, perceived bleeding risk, or moderate renal impairment alone—this is the most common prescribing error with apixaban, occurring in 9.4-40.4% of prescriptions. 3 The dose reduction to 2.5 mg twice daily requires meeting ≥2 criteria, not just one. 1, 3, 4

Renal Function Considerations

Apixaban has only 27% renal clearance, making it the safest direct oral anticoagulant in renal impairment compared to dabigatran (80% renal) or rivaroxaban (66% renal). 1, 3, 2

Dosing by creatinine clearance (using Cockcroft-Gault equation, NOT eGFR): 1, 3

CrCl (mL/min)	Apixaban Dose	Requirement
>30	5 mg twice daily	Unless ≥2 dose-reduction criteria met
15-29	2.5 mg twice daily	Mandatory for ALL patients
<15 or dialysis	5 mg twice daily*	*Reduce to 2.5 mg BID if age ≥80 OR weight ≤60 kg (only ONE criterion needed)

1, 3

Since your patient has CrCl ≥30 mL/min, use the standard 5 mg twice daily dose unless ≥2 criteria are met. 1, 3

How to Execute the Transition

Stop warfarin and start apixaban when the INR drops below 2.0. 3, 4 This approach avoids overlapping anticoagulation and reduces bleeding risk. 3

Practical transition steps: 3, 4

1. Check INR
2. When INR <2.0, discontinue warfarin
3. Start apixaban 5 mg twice daily at the time of the next scheduled warfarin dose
4. No bridging anticoagulation needed
5. No loading dose required

Advantages Over Warfarin

No routine INR monitoring required. 1, 2 This directly addresses the patient's concern about blood draws. 1, 2

No dietary restrictions. 3 Unlike warfarin, apixaban does not interact with vitamin K-containing foods. 3

More predictable anticoagulation effect with lower risk of warfarin-related nephropathy (which occurs twice as frequently in CKD patients on warfarin). 3, 5

Monitoring Requirements After the Switch

Renal function should be reassessed at least annually. 1, 2 If CrCl <60 mL/min, increase monitoring frequency to every 3-6 months. 1, 2

No routine anticoagulation monitoring (INR) is needed. 1, 2

Monitor for bleeding symptoms clinically, particularly gastrointestinal bleeding in older adults. 1

Drug Interactions to Screen

Reduce apixaban to 2.5 mg twice daily if the patient is taking combined P-glycoprotein AND strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, itraconazole). 1, 4

Avoid apixaban entirely with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort). 1, 4

Contraindications to Verify

Confirm the patient does NOT have: 2, 4

• Mechanical heart valve (absolute contraindication)
• Moderate-to-severe mitral stenosis
• Active pathological bleeding
• Severe hepatic dysfunction (transaminases >2× upper limit or bilirubin >1.5× upper limit)

Special Consideration: Prior Pulmonary Embolism

Apixaban is FDA-approved for treatment of PE and reduction of recurrent VTE risk. 4 For a patient with prior PE requiring lifelong anticoagulation, apixaban provides the same indication coverage as warfarin. 4

The dosing algorithm for atrial fibrillation applies equally to VTE prevention in this chronic anticoagulation scenario. 1, 4

Bottom Line

Switch this patient to apixaban 5 mg twice daily (assuming <2 dose-reduction criteria are met), stop warfarin when INR <2.0, and eliminate routine INR monitoring. 1, 3, 2, 4 This provides superior or equivalent efficacy with significantly lower bleeding risk compared to warfarin, directly addressing the patient's concern about blood draws while maintaining optimal stroke and PE prevention. 1, 2